Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (Nasdaq: ENLV) reported that, as of July 29, 2026, trading volume on the Rain protocol reached $860 million, representing 622% month-over-month growth in July 2026 versus June 2026. The update relates to Enlivex’s RAIN token-based prediction markets treasury portfolio.
According to Enlivex, the Rain Foundation currently projects Rain protocol trading volumes of $1.3 billion in 2027, $12 billion in 2028 and $33 billion in 2029. At those levels, Rain Foundation expects gross fees of $49 million, $436 million and $1.2 billion, and net buy-and-burn allocations of $24 million, $216 million and $600 million, respectively. Enlivex highlights public, unaudited mark-to-market treasury metrics on its website and notes that detailed RAIN token data is available on CoinMarketCap.
The company reiterates its dual strategy: advancing Allocetra, a clinical-stage immunotherapy targeting age-related osteoarthritis, while maintaining exposure to the decentralized prediction markets ecosystem through the Rain protocol.
Enlivex (Nasdaq: ENLV) will host a live investor webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time. Management plans to discuss the rationale and intended use of proceeds for its recently announced private placement, the status and long-term strategy of its Rain protocol-based RAIN treasury, and recent clinical progress of Allocetra™, including its new Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for symptomatic knee osteoarthritis in patients aged 64 and older. Investors can register at the provided RedChip webinar link.
Enlivex (Nasdaq: ENLV) entered into a securities purchase agreement with a single institutional investor for a private placement of approximately $400,000,000 of ordinary shares (or equivalents). Shares funded in U.S. dollars, USDT or USD Coin are priced at $5.00, and shares funded in RAIN tokens are priced at $6.00, representing premiums of 17.4% and 40.8%, respectively, to the July 27, 2026 closing price.
The investor has currently elected to fund the purchase in RAIN tokens, which may be changed before closing. Enlivex plans to use net proceeds to advance its Rain protocol-based treasury strategy and its clinical-stage immunotherapy Allocetra™, focused on age-related osteoarthritis. The agreement grants Enlivex a discretionary right, for 36 months post-closing, to require the investor to purchase up to an additional $400,000,000 of securities on the same pricing terms. Closing is subject to shareholder approval under Nasdaq Listing Rules 5635(a), 5635(b) and Section 274 of the Israeli Companies Law, after which Enlivex expects to consummate the Transaction.
Enlivex (Nasdaq: ENLV) reported updated treasury metrics tied to its RAIN token holdings. As of July 18, 2026, net asset value (NAV) per ordinary share was $66.16, and the company held 79,550,593,122 RAIN tokens valued at approximately $1.1 billion, based on closing prices on CoinMarketCap.
According to Enlivex, these figures are unaudited mark-to-market valuations and are available on its online treasury dashboard. The company couples its clinical-stage Allocetra immunotherapy programs in age-related osteoarthritis with a prediction markets treasury strategy centered on the Rain protocol.
Enlivex (Nasdaq: ENLV) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy for age-related symptomatic primary knee osteoarthritis in patients aged 64 and older. RMAT status is intended to accelerate development of regenerative therapies that show preliminary evidence of addressing unmet medical needs in serious conditions.
According to Enlivex, RMAT designation enables intensive, early FDA interaction and potential eligibility for accelerated approval and priority review. The designation was based on a completed Phase I/IIa trial in which Allocetra™ showed statistically significant and clinically meaningful improvements in knee pain and physical function versus placebo, with durable efficacy for at least six months. Enlivex has initiated a randomized, controlled Phase IIb trial in the U.S. and EU, targeting 182 patients in this age group, and expects top-line data by the end of Q2 2027. The FDA has requested a Type B meeting to discuss the Allocetra™ program and align on Phase IIb and pivotal development plans.
Enlivex (Nasdaq: ENLV) approved a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026, when trading will begin on a split-adjusted basis.
Authorized shares decrease from 2,375,000,000 to 158,333,334, outstanding shares to about 16,832,015, with unchanged ownership percentages and voting rights.
Enlivex (Nasdaq: ENLV) announced that its primary treasury asset, the RAIN token, is expected to list on the Gate cryptocurrency exchange on June 24, 2026 at 10:00 AM UTC. Gate is described as serving over 54 million users and ranking second globally in 24-hour spot trading volume.
Enlivex focuses its digital treasury strategy on acquiring RAIN. As of June 21, 2026, it reportedly held 79,568,550,005 RAIN valued at approximately $1.14 billion, implying a treasury NAV per share of $4.67. The listing is expected to broaden access and secondary liquidity for RAIN.
Enlivex (Nasdaq: ENLV) reported updated treasury metrics tied to its RAIN token holdings. As of June 20, 2026, Enlivex held 79,568,550,005 RAIN tokens valued at approximately $1.14 billion. Treasury NAV per Share was $4.671, based on current RAIN holdings and ordinary shares outstanding.
Enlivex (Nasdaq: ENLV) announced issuance of Australian patent 2020340629 covering methods of using Allocetra™ to treat osteoarthritis. The patent provides protection in Australia through at least 2040, expanding Allocetra’s osteoarthritis IP coverage as a Phase 2b knee osteoarthritis trial advances with the first U.S. patient dosed.
Enlivex (Nasdaq: ENLV) announced it is a Gold Sponsor of Proof of Talk 2026, held June 2-3, 2026 at the Louvre Palace and Musée des Arts Décoratifs in Paris.
CEO Dr. Oren Hershkovitz will present Enlivex's quality longevity model powered by a prediction markets treasury at a curated institutional investor dinner.